<h4>Importance</h4>Albumin supplementation may reduce mortality in patients with septic shock; however, data from randomized clinical trials are limited.<h4>Objective</h4>To assess the impact of albumin administration on outcomes in patients with septic shock.<h4>Design, setting, and participants</h4>This multicenter, open-label randomized clinical trial was conducted between October 21, 2019, and May 2, 2022. This evidence concerns the gene ALB and Shock.